Abstract
Cytoplasmic and nuclear iron-sulfur enzymes that are essential for genome maintenance and replication depend on the cytoplasmic iron-sulfur assembly (CIA) machinery for cluster acquisition. Here we report that patients with biallelic loss of function in CIAO1, a key CIA component, develop proximal and axial muscle weakness, fluctuating creatine kinase elevation and respiratory insufficiency. In addition, they present with CNS symptoms including learning difficulties and neurobehavioral comorbidities, along with iron deposition in deep brain nuclei, macrocytic anemia and gastrointestinal symptoms. Mutational analysis and functional assays revealed reduced stability of the variants compared to wild-type CIAO1. Loss of CIAO1 impaired DNA helicases, polymerases and repair enzymes which rely on the CIA complex to acquire their Fe-S cofactors, with lentiviral restoration reversing all patient-derived cellular abnormalities. Our study identifies CIAO1 as a novel human disease gene and provides insights into the broader implications of the iron-sulfur assembly pathway in human health and disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Intramural funds from the NIH National Institute of Neurological Disorders and Stroke (grant to C.G.B) and from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (to T.A.R.). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Work carried out as part of this study has received support from The Solve-RD project, funded from the European Unions Horizon 2020 research and innovation programme under grant agreement No 779257, from the Muscular Dystrophy Association under grant agreement MDA577346 (Novel CMD and CMY genes: Discovery and functional analysis and from the Muscular Dystrophy UK (1GRO-PG24-0271). The support of the MRC Centre for Neuromuscular Diseases (MRC CNMD) Biobank London, is gratefully acknowledged. F Muntoni is supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J. Brazzo Foundation, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK, and Coalition to Cure Calpain 3. AT has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of National Institutes of Health gave ethical approval for this work (protocol 12N0095); Ethics committee of Great Ormond Street Hospital gave ethical approval for this work (GOSH 00/5802); National Research Ethics Service (NRES) Committee of North East Newcastle & North Tyneside 1 gave ethical approval for this work (reference 19/NE/0028).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- CIA
- Cytoplasmic Iron-sulfur Assembly
- CK
- Creatine Kinase
- CNS
- central nervous system
- COX
- Cytochrome c Oxidase
- EM
- Electron Microscopy
- FVC
- forced vital capacity
- H&E
- Hematoxylin and Eosin
- ISC(s)
- Iron Sulfur Cluster(s)
- NADH-TR
- Nicotinamide Adenine Dinucleotide Tetrazolium Reductase
- QSM
- Quantitative Susceptibility Mapping
- SDH
- Succinic Dehydrogenase
- SWI
- Susceptibility Weighted Imaging
